SCHEMBL12633852

SCHEMBL12633852

CC1(C)CCC(C)(C)c2cc(-c3cc(F)cc(N4CCN(CCCCCO)CC4)c3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 3/20 0.39
RARB P10826 3/20 0.39
RARG P13631 3/20 0.39
HTR1A P08908 5/20 0.37
HTR7 P34969 4/20 0.37
HTR6 P50406 2/20 0.37
HRH1 P35367 2/20 0.37
HRH2 P25021 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 4/20 0.36
DRD2 P14416 4/20 0.36
DRD3 P35462 4/20 0.36
DRD4 P21917 2/20 0.36
HTR2A P28223 2/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
DRD1 P21728 1/20 0.34
DRD5 P21918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012784 0.86 KCNH2 (0.49) RARARARBRARGHTR1AHTR7
SCHEMBL2037348 0.85 KCNH2 (0.47) RARARARBRARGHTR7KCNH2
SCHEMBL12633854 0.84 RARB (0.39) RARARARBRARGHRH3KCNH2
SCHEMBL2049682 0.79 HRH4 (0.41) RARARARBRARGHTR1AHTR7
SCHEMBL12959460 0.78 RARA (0.45) RARARARBRARGHTR1AHTR7
SCHEMBL2014962 0.78 RARA (0.45) RARARARBRARGHTR1AHTR7
SCHEMBL2014118 0.77 LRRK2 (0.42) RARARARBRARGHTR1AHRH3
SCHEMBL12632929 0.76 RARA (0.46) RARARARBRARGHTR1AHTR7
SCHEMBL12515947 0.76 HRH3 (0.43) RARARARBRARGHRH3KCNH2
SCHEMBL2223781 0.76 ABCB1 (0.41) RARARARBRARGDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 RARA 4373/4885RARB 4194/4885RARG 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.